Rabinovici Gil D, Knopman David S, Arbizu Javier, Benzinger Tammie L S, Donohoe Kevin J, Hansson Oskar, Herscovitch Peter, Kuo Phillip H, Lingler Jennifer H, Minoshima Satoshi, Murray Melissa E, Price Julie C, Salloway Stephen P, Weber Christopher J, Carrillo Maria C, Johnson Keith A
Department of Neurology and Department of Radiology and Biomedical Imaging, University of California at San Francisco, San Francisco, California;
Mayo Clinic Neurology and Neurosurgery, Rochester, Minnesota.
J Nucl Med. 2025 Jan 8. doi: 10.2967/jnumed.124.268756.
The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as "rarely appropriate," "uncertain," or "appropriate." Ratings were performed separately for amyloid and tau PET as stand-alone modalities. For amyloid PET, 7 scenarios were rated as appropriate, 2 as uncertain, and 8 as rarely appropriate. For tau PET, 5 scenarios were rated as appropriate, 6 as uncertain, and 6 as rarely appropriate. AUC for amyloid and tau PET provide expert recommendations for clinical use of these technologies in the evolving landscape of diagnostics and therapeutics for Alzheimer's disease.
阿尔茨海默病协会与核医学和分子影像学会召集了一个多学科工作组，以更新淀粉样蛋白正电子发射断层扫描（PET）的适当使用标准（AUC），并制定tau PET的AUC。该工作组确定了关键研究问题，这些问题指导了对临床淀粉样蛋白/tau PET的系统文献综述。在此综述的基础上，工作组制定了17种可能考虑使用淀粉样蛋白或tau PET的临床场景。采用改良的德尔菲法，通过共识将每种场景评为“很少适用”、“不确定”或“适用”。作为独立模态，分别对淀粉样蛋白PET和tau PET进行评级。对于淀粉样蛋白PET，7种场景被评为适用, 2种为不确定，8种为很少适用。对于tau PET，5种场景被评为适用，6种为不确定，6种为很少适用。淀粉样蛋白和tau PET的AUC为这些技术在阿尔茨海默病诊断和治疗不断发展的格局中的临床应用提供了专家建议。
